ATE497784T1 - Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen - Google Patents
Arznei zur prävention und behandlung von herzerkrankungen mit cd9-genInfo
- Publication number
- ATE497784T1 ATE497784T1 AT04808124T AT04808124T ATE497784T1 AT E497784 T1 ATE497784 T1 AT E497784T1 AT 04808124 T AT04808124 T AT 04808124T AT 04808124 T AT04808124 T AT 04808124T AT E497784 T1 ATE497784 T1 AT E497784T1
- Authority
- AT
- Austria
- Prior art keywords
- gene
- heart diseases
- diseases
- drug
- heart
- Prior art date
Links
- 208000019622 heart disease Diseases 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 101150036788 CD9 gene Proteins 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000013604 expression vector Substances 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 238000001415 gene therapy Methods 0.000 abstract 2
- 239000013603 viral vector Substances 0.000 abstract 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 208000002330 Congenital Heart Defects Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000001871 Tachycardia Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 208000015210 hypertensive heart disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 230000006794 tachycardia Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003432279 | 2003-12-26 | ||
| PCT/JP2004/019774 WO2005063302A1 (ja) | 2003-12-26 | 2004-12-24 | Ｃｄ９遺伝子からなる心疾患を予防又は治療する医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE497784T1 true ATE497784T1 (de) | 2011-02-15 |
Family
ID=34736470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04808124T ATE497784T1 (de) | 2003-12-26 | 2004-12-24 | Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7803780B2 (de) |
| EP (1) | EP1716869B1 (de) |
| JP (1) | JP4736088B2 (de) |
| AT (1) | ATE497784T1 (de) |
| DE (1) | DE602004031381D1 (de) |
| WO (1) | WO2005063302A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013200106B2 (en) * | 2006-04-21 | 2015-10-01 | Intervet International Bv | Pestivirus Species |
| KR20200122601A (ko) * | 2019-04-18 | 2020-10-28 | 황정후 | Cd9을 이용한 퇴행성 신경질환의 예방 또는 치료용 조성물과 퇴행성 신경질환 치료제 스크리닝 방법 |
| US11905249B2 (en) | 2021-01-25 | 2024-02-20 | Jackson State University | Covalent inhibitors of equine encephalitis virus |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001523103A (ja) * | 1997-04-28 | 2001-11-20 | ローヌ−プーラン・ロレ・エス・アー | 腫瘍治療用血管形成アンタゴニストのアデノウイルスによる腫瘍内送達 |
| US7060433B1 (en) * | 1999-11-12 | 2006-06-13 | Rigel Pharmaceuticals, Inc. | Methods and compositions for screening using diphtheria toxin constructs |
-
2004
- 2004-12-24 JP JP2005516732A patent/JP4736088B2/ja not_active Expired - Fee Related
- 2004-12-24 AT AT04808124T patent/ATE497784T1/de not_active IP Right Cessation
- 2004-12-24 EP EP04808124A patent/EP1716869B1/de not_active Expired - Lifetime
- 2004-12-24 US US10/584,109 patent/US7803780B2/en not_active Expired - Fee Related
- 2004-12-24 WO PCT/JP2004/019774 patent/WO2005063302A1/ja not_active Ceased
- 2004-12-24 DE DE602004031381T patent/DE602004031381D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4736088B2 (ja) | 2011-07-27 |
| EP1716869A4 (de) | 2007-05-23 |
| WO2005063302A1 (ja) | 2005-07-14 |
| EP1716869B1 (de) | 2011-02-09 |
| EP1716869A1 (de) | 2006-11-02 |
| DE602004031381D1 (de) | 2011-03-24 |
| US20070161584A1 (en) | 2007-07-12 |
| US7803780B2 (en) | 2010-09-28 |
| JPWO2005063302A1 (ja) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL378030A1 (pl) | Czynniki które regulują, hamują lub modulują działanie i/lub wyrażanie czynnika wzrostowego tkanki łącznej (CTGF), jako wyjątkowe środki do obniżania ciśnienia śródgałkowego i leczenia retinopatii jaskrowej/neuropatii nerwu wzrokowego | |
| CA2278842A1 (en) | Use of peroxygen compounds in the control of hairy wart disease | |
| CY1110400T1 (el) | Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων | |
| DE69718612D1 (de) | Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung | |
| EP1461352A4 (de) | Antisense-modulation der expression von bindegewebewachstumsfaktor | |
| NO20044940L (no) | Rekombinant poxvirus som uttrykker homologe gener innsatt i det poxvirale genomet | |
| DE60019473D1 (de) | (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien | |
| DE60028863D1 (de) | Elektrochirurgisches Handstück zur Behandlung von Gewebe | |
| ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| ATE491715T1 (de) | Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten | |
| DE60009146D1 (de) | Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten | |
| EP1343532A4 (de) | Durch lentiviralen vektor vermittelter gentransfer und anwendungszwecke | |
| ATE497784T1 (de) | Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen | |
| DE60231649D1 (de) | Mittel zur behandlung von augentrockenheit und damit zusammenhängenden erkrankungen | |
| DE60111620D1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
| DE60231246D1 (de) | Superoxiddismutas-mimetika zur behandlung von augenerkrankungen | |
| DE602005020178D1 (de) | 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten | |
| AP9901474A0 (en) | Pharmaceutical composition for treating viral diseases. | |
| DE69621786D1 (de) | Aminotetralinderivat zur behandlung von herzkreislauferkrankung | |
| ATE285764T1 (de) | Rivastigmine zur behandlung von augenerkrankungen | |
| MXPA05004121A (es) | Metodos para tratar la enfermedad de ojo reseco con lantibioticos. | |
| EP1062948A4 (de) | Arzneimittel für diastolische herzerkrankungen | |
| DE60124093D1 (de) | S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen. | |
| ATE239492T1 (de) | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen | |
| WO2003016343A3 (en) | USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |